Intensified induction therapy with behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine and prednisolone (BHAC-DMP (II)) Therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration

R. Ohno, M. Okumura, S. Yokomaku, Y. Ito, K. Yano, I. T. Sugiura Kataoka, T. Nagai, M. Hamaguchi, T. Kumazawa, T. Murase, T. Kojima, M. Tanimoto, Y. Morishita, E. Nagura, M. Ogura, Y. Morishima, Y. Kodera, K. Kawashima, H. Saito

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Intensified induction therapy with behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine and prednisolone (BHAC-DMP (II)) Therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration'. Together they form a unique fingerprint.